NASDAQ:BCTX Briacell Therap (BCTX) Stock Price, News & Analysis $13.79 +0.65 (+4.95%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$13.64 -0.15 (-1.12%) As of 10/24/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Briacell Therap Stock (NASDAQ:BCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Briacell Therap alerts:Sign Up Key Stats Today's Range$12.66▼$13.9050-Day Range$6.55▼$13.7952-Week Range$6.00▼$190.50Volume81,884 shsAverage Volume96,795 shsMarket Capitalization$9.38 millionP/E RatioN/ADividend YieldN/APrice Target$320.00Consensus RatingHold Company Overview BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Read More Briacell Therap Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreBCTX MarketRank™: Briacell Therap scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBriacell Therap has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBriacell Therap has a consensus price target of $320.00, representing about 2,220.5% upside from its current price of $13.79.Amount of Analyst CoverageBriacell Therap has only been the subject of 1 research reports in the past 90 days.Read more about Briacell Therap's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Briacell Therap are expected to grow in the coming year, from ($2.45) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Briacell Therap is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Briacell Therap is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBriacell Therap has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Briacell Therap's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.15% of the float of Briacell Therap has been sold short.Short Interest Ratio / Days to CoverBriacell Therap has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Briacell Therap has recently increased by 567.39%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBriacell Therap does not currently pay a dividend.Dividend GrowthBriacell Therap does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.15% of the float of Briacell Therap has been sold short.Short Interest Ratio / Days to CoverBriacell Therap has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Briacell Therap has recently increased by 567.39%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.07 News SentimentBriacell Therap has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Briacell Therap this week, compared to 2 articles on an average week.Search Interest13 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Briacell Therap to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Briacell Therap insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.73% of the stock of Briacell Therap is held by insiders.Percentage Held by InstitutionsOnly 15.42% of the stock of Briacell Therap is held by institutions.Read more about Briacell Therap's insider trading history. Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Briacell Therap and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCTX Stock News HeadlinesBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerOctober 22 at 7:30 AM | globenewswire.comBriaCell adds clinical sites in Phase 3 metastatic breast cancer studyOctober 21, 2025 | msn.comTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…October 25 at 2:00 AM | Brownstone Research (Ad)BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer StudyOctober 21, 2025 | globenewswire.comBriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast CancerOctober 21, 2025 | globenewswire.comBriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025October 20, 2025 | globenewswire.comBriacell Therap (BCTX) to Release Quarterly Earnings on MondayOctober 20, 2025 | americanbankingnews.comBriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025October 13, 2025 | globenewswire.comSee More Headlines BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? Briacell Therap's stock was trading at $84.75 on January 1st, 2025. Since then, BCTX stock has decreased by 83.7% and is now trading at $13.79. How were Briacell Therap's earnings last quarter? Briacell Therap (NASDAQ:BCTX) released its quarterly earnings results on Friday, June, 13th. The company reported ($16.40) EPS for the quarter, beating the consensus estimate of ($17.60) by $1.20. When did Briacell Therap's stock split? Shares of Briacell Therap reverse split on Tuesday, August 26th 2025.The 1-10 reverse split was announced on Tuesday, August 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Briacell Therap IPO? Briacell Therap (BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Briacell Therap? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Briacell Therap own? Based on aggregate information from My MarketBeat watchlists, some other companies that Briacell Therap investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Plug Power (PLUG), Micron Technology (MU) and Permian Basin Royalty Trust (PBT). Company Calendar Last Earnings6/13/2025Today10/25/2025Next Earnings (Estimated)10/27/2025Fiscal Year End7/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCTX CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees8Year Founded2004Price Target and Rating Average Price Target for Briacell Therap$320.00 High Price Target$320.00 Low Price Target$320.00 Potential Upside/Downside+2,220.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($83.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-291.42% Return on Assets-180.62% Debt Debt-to-Equity RatioN/A Current Ratio5.01 Quick Ratio5.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.58 per share Price / Book0.54Miscellaneous Outstanding Shares680,000Free Float639,000Market Cap$9.38 million OptionableNo Data Beta1.21 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BCTX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.